AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-13 (canceled)

Claim 14 (previously presented): A method of inhibiting TGFβ-induced cataract or after-cataract formation in the eye of a mammalian subject in need of such inhibition, which comprises the step of administering to the subject an effective amount of one or more inhibitors of TGFβ.

Claim 15 (previously presented): The method according to claim 14 wherein the one or more inhibitors of TGFβ are selected from proteins, gycloproteins and proteoglycans.

Claim 16 (previously presented): The method according to claim 15 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 17 (previously presented): The method according to claim 15 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 18 (previously presented): The method according to claim 15 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 19 (previously presented): An ophthalmological formulation comprising one or more inhibitors of TGFβ in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.

Claim 20 (previously presented): The ophthalmological formulation according to claim 19 wherein the one or more inhibitors of TGFβ are selected from proteins, glycoproteins and proteoglycans.

Claim 21 (previously presented): The ophthalmological formulation according to claim 20 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 22 (previously presented): The ophthalmological formulation according to claim 20 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 23 (previously presented): The ophthalmological formulation according to claim 20 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 24 (previously presented): A method of inhibiting after-cataract formation in the eye of a mammalian subject following lens implant surgery, which comprises the step of implanting in the eye of the subject a lens coated with one or more TGFβ inhibitors.

Claim 25 (previously presented): The method according to claim 24 wherein the one or more inhibitors of TGFβ are selected from proteins, glycoproteins and proteoglycans.

Claim 26 (previously presented): The method according to claim 25 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 27 (previously presented): The method according to claim 25 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 28 (previously presented): The method according to claim 25 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 29 (withdrawn): A lens implant comprising a coating, the coating including one or more TGFβ inhibitors.

Claim 30 (withdrawn): The lens implant according to claim 29 coated with one or more TGFβ inhibitors selected from proteins, glycoproteins and proteoglycans.

Claim 31 (withdrawn): The lens implant according to claim 30 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 32 (withdrawn): The lens implant according to claim 30 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 33 (withdrawn): The lens implant according to claim 30 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claims 34-38 (canceled)

Claim 39 (previously presented): An ophthalmological formulation formulated for introduction into one or more chambers of the eye, the formulation comprising one or more inhibitors of TGFβ.

Claim 40 (currently amended): An ophthalmological formulation according to claim 39 wherein the one or more inhibitors of TGFβ are in an irrigation solution or viscoelastic solution.

Claim 41 (previously presented): The ophthalmological formulation according to claim 40 wherein the one or more inhibitors of TGFβ are selected from proteins, glycoproteins and proteoglycans.

Claim 42 (previously presented): The ophthalmological formulation according to claim 41 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 43 (previously presented). The ophthalmological formulation according to claim 41 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 44 (previously presented): The ophthalmological formulation according to claim 41 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.